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Grade 3/4 AEs occurred in 40.6% (geﬁtinib) and 81.6% (docetaxel) 
of patients. The incidence of interstitial lung disease (ILD) was 5.7% 
(n=14) and 2.9% (n=7) with geﬁtinib and docetaxel, respectively. There 
were four deaths due to AEs in the geﬁtinib arm (three possibly treat-
ment-related due to ILD; one due to pneumonia that was not considered 
treatment-related), and none in the docetaxel arm. Biomarker data will 
also be reported.
Conclusions: Non-inferiority in overall survival between geﬁtinib 
and docetaxel was not demonstrated according to predeﬁned criteria. 
However, there was no statistically signiﬁcant difference in survival 
between the two groups. Imbalances in the proportion and type of 
post-study treatments in both arms have complicated interpretation of 
survival results. The secondary endpoints are largely unaffected by 
subsequent therapy and provide further evidence of the clinical efﬁcacy 
of geﬁtinib in Japanese patients. AEs were consistent with those previ-
ously observed for both treatments.
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Background: It is estimated that 30-40% of patients with advanced 
non-small-cell lung cancer (NSCLC) have a poor performance status 
(PS); however, there is no consensus on the best treatment approach 
for such patients (Gridelli et al, Ann Oncol 2004;15:419-426). In a 
large randomized four arm, Phase III study, the median survival for 
PS2 patients treated with combination chemotherapy was 3.9 months 
(Schiller et al, NEJM 2002;346:92-98). Single-agent chemotherapy is 
also an option for PS2 patients (Gridelli et al, Lung Cancer 2002;38:
S37-S41) but there is a need for effective treatment alternatives for pa-
tients considered unﬁt for chemotherapy or who refuse chemotherapy. 
A retrospective review of 198 chemotherapy-naïve patients (20% PS2 
and 3) with advanced NSCLC who received geﬁtinib (IRESSA) within 
a compassionate use program in the USA, reported a median survival 
of 6 months and objective response rate of 6.3% (Govindan et al. Lung 
Cancer 2006;53:331-337). The Phase II, randomized, double-blind, 
multicenter, parallel-group study reported here compared geﬁtinib plus 
BSC to placebo plus BSC in patients with advanced NSCLC and poor 
PS (IRESSA NSCLC Trial Evaluating Poor PS patients [INSTEP]).
Methods: This study planned to recruit approximately 200 patients. 
Following written, informed consent, patients (≥18 years) with locally 
advanced or metastatic (stage IIIB or IV) NSCLC who were chemo-
therapy-naïve, had a poor PS (WHO PS 2 or 3) and were considered 
unﬁt for chemotherapy were randomized to geﬁtinib (250 mg/day 
orally) plus BSC or placebo plus BSC. The primary objective of this 
study was to compare progression-free survival (PFS) between the 
two treatment groups. Secondary endpoints were objective response 
rate (assessed every 6 weeks using RECIST criteria), overall survival, 
patient-reported functionality and quality of life (via the Functional 
Assessment of Cancer Therapy-Lung [FACT-L] trial outcome index 
and total score, respectively), pulmonary symptom improvement (as 
measured by the pulmonary items of the FACT-L lung cancer sub-
scale), and tolerability (frequency and severity of adverse events [via 
CTC version 3.0] and laboratory parameters). An exploratory endpoint 
was to correlate the efﬁcacy of geﬁtinib with epidermal growth factor 
receptor (EGFR) gene copy number. A proportional hazards model 
(presenting a hazard ratio and its associated 95% conﬁdence intervals) 
will be used to compare PFS between treatment groups, with gender, 
PS, histology, smoking history, and stage as covariates. While median 
PFS on BSC is expected to be in the region of 4 weeks, there are no 
data upon which to accurately anticipate the effectiveness of geﬁtinib in 
this setting. With 200 patients recruited, this study would have greater 
than 90% power to detect a 75% improvement in PFS and 81% power 
to detect a 50% improvement in PFS.
Results: Between September 2004 and December 2006, 201 patients 
were randomized from 5 countries and 37 centers. Efﬁcacy, quality of 
life, safety and EGFR gene copy number results will be available for 
presentation at this meeting.
Conclusions: To be completed once data are available.
IRESSA is a trademark of the AstraZeneca group of companies
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Background: Cetuximab (Erbitux®) is a chimeric monoclonal IgG1 
antibody targeting the epidermal growth factor receptor (EGFR) 
thereby blocking ligand-receptor interaction, promoting receptor 
internalization, cell cycle arrest and apoptosis. Several phase II studies 
with cetuximab in combination with platinum based chemotherapy 
have shown encouraging anti-tumor activity in patients with advanced/
metastatic NSCLC. This randomized phase III study was conducted to 
determine the efﬁcacy of adding cetuximab to taxane/platinum chemo-
therapy in patients with recurrent or metastatic NSCLC in a random-
ized controlled setting.
Methods: Patients with previously untreated stage IIIB (malignant 
pleural effusion) or stage IV NSCLC were eligible for this study. Pa-
tients on arm A received cetuximab (400 mg/m2 IV on day 1 followed 
by 250 mg/m2 weekly) combined with either paclitaxel (225 mg/m2 IV 
q3 weeks) or docetaxel (75mg mg/m2 IV q3 weeks) and carboplatin 
(AUC 6 IV q3 weeks). Patients on Arm B received the same chemo-
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therapy regimen but without cetuximab. The choice of taxane was at 
the discretion of the investigator but had to be made before randomiza-
tion since on-study taxane (paclitaxel or docetaxel), ECOG PS (0 vs. 
1) and site were part of the stratiﬁcation scheme. The primary endpoint 
was progression-free-survival (PFS) as determined by an Independent 
Radiology Review Committee. In order to have 90% power to detect 
a hazard ratio of 0.75 of the combination arm over the control arm 
510 progression events were required. Secondary endpoints included 
response rate, time to response, duration of response, disease control 
rate, quality of life and overall survival (OS). 
Results and Conclusions: From December 2004 until October 2006 
676 patients were randomized at 97 centers in the US: 58.6% men, 41.4 
% women with a median age of 65 years (range 34-87). Data on the 
primary and secondary objectives along with unblinded safety data will 
be presented at the meeting.
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Background: This Phase II, open-label, parallel-group study (INVITE 
[IRESSA in NSCLC vs Vinorelbine Investigation in The Elderly]) 
compared geﬁtinib (IRESSA) with vinorelbine in chemonaïve elderly 
patients with locally advanced or metastatic non small-cell lung cancer.
Methods: Patients (≥70 years; performance status ≤2) were random-
ized to geﬁtinib (250 mg/day orally) or vinorelbine (30 mg/m2 infusion 
on Days 1 and 8 of a 21 day cycle). The primary endpoint was progres-
sion-free survival (PFS). Secondary endpoints were overall survival 
(OS), objective response rate (ORR; assessed by RECIST), quality 
of life (QoL; assessed by Functional Assessment of Cancer Therapy 
Lung [FACT-L] and improvement in the physical aspects of QoL as 
measured by the trial outcome index [TOI]), pulmonary symptom 
improvement (PSI; assessed by the 4 pulmonary items of the lung 
cancer symptoms subscale [LCS] of the FACT-L) and adverse event 
(AE) proﬁle. Exploratory analysis included EGFR gene copy number 
by ﬂuorescence in situ hybridization (FISH), EGFR protein expression 
and EGFR mutation analysis.
Results: 196 patients (75.5% male, 85.7% regular/ex smokers, 40.3% 
adenocarcinoma) from a total of 10 countries were randomized to 
geﬁtinib (n=97) or vinorelbine (n=99). Hazard ratios (HR) for PFS 
and OS were 1.19 (95% CI 0.85, 1.65) and 0.98 (95% CI 0.66, 1.47), 
respectively, for geﬁtinib vs vinorelbine. ORR and disease control rates 
were 3.1% and 43.3% (geﬁtinib) and 5.1% and 53.5% (vinorelbine), re-
spectively. FACT-L QoL improvement rates were higher with geﬁtinib 
vs vinorelbine (24.3% vs 10.9%, respectively) as was the TOI (22.9% 
vs 6.3%, respectively). Symptom improvement rates appeared similar 
with geﬁtinib vs vinorelbine: 36.6% vs 31.0% for PSI and 42.9% vs 
39.1% on the LCS. In the EGFR FISH-positive subgroup (n=54), HRs 
for geﬁtinib vs vinorelbine were 3.13 (95% CI 1.45, 6.76) for PFS and 
2.88 (95% CI 1.21, 6.83) for OS. In the EGFR FISH-negative subgroup 
(n=104), HRs for geﬁtinib vs vinorelbine were 0.93 (95% CI 0.59, 
1.46) for PFS and 0.79 (95% CI 0.46, 1.37) for OS. Few patients had 
tumor samples that were EGFR protein expression negative (13/157 
[8.3%] patients) or EGFR mutation-positive (7/65 [10.8%] patients), 
precluding further analysis of these data. The geﬁtinib arm had fewer 
treatment-related grade 3-5 AEs compared with vinorelbine (12.8% vs 
41.7%). The most common AEs were rash and diarrhea for geﬁtinib, 
and constipation, fatigue and neutropenia for vinorelbine. There were 
three treatment-related deaths in the vinorelbine arm, and none in the 
geﬁtinib arm.
Conclusions: Although the primary endpoint of demonstrating superior 
PFS for geﬁtinib relative to vinorelbine was not met, geﬁtinib was 
broadly similar to vinorelbine in terms of PFS, OS and ORR in this 
ﬁrst-line study in elderly patients. Geﬁtinib was better tolerated than 
vinorelbine. Overall QoL improvement, including TOI, was increased 
with geﬁtinib compared with vinorelbine, while PSI and LCS was 
similar in both arms. The difference between geﬁtinib and vinorelbine 
in the small exploratory analyses of FISH positive patients requires 
further investigation.
IRESSA is a trademark of the AstraZeneca group of companies
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Background: Meta-analyses based on data extracted from the literature 
rather than on individual patient data (IPD) must be interpreted with 
caution. We compare here results obtained with 3 sources: published 
data, study report data and IPD in analyzing randomized studies com-
paring docetaxel to vinca-alkaloïds in ﬁrst line treatment of NSCLC.
Material and Methods: Study search and selection have been previ-
ously described [Douillard JY et al. Proc ASCO 2006]. Summary sta-
tistics to perform a meta-analysis of published data were either directly 
extracted (hazard ratio (HR) and 95% CI available) or derived from 
the number of deaths and log-rank p value [Parmar M et al. Stat Med 
1998; 17: 2815-34]. Summary statistics of the study report data were 
either directly extracted, derived, or computed using life tables. All 
analyses were performed on an intention-to-treat basis when available. 
Logarithms of the HR were pooled by the inverse-variance weighting 
method. For IPD, the meta-analysis was performed by a log-rank test 
stratiﬁed for study.
